Drugs / KSP/QRH dimer
KSP/QRH dimer
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03852576 | May 2019 → Nov 2020 | Barrett esophagus | University of Michigan | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSP/QRH dimer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03852576 ↗ |
| Known as | KSP-QRH-E3-IRDye800 | “KSP-QRH-E3-IRDye800 (Peptide 919288G)” NCT03852576 ↗ |
| Known as | Peptide 919288G | “KSP-QRH-E3-IRDye800 (Peptide 919288G)” NCT03852576 ↗ |
| Modality | Peptide | “Peptide monomers specific for EGFR and ErbB2 were arranged in a heterodimer configuration” PMID 35299273 ↗ Mar 2022 |
| Route | Topical | “This near-infrared (NIR) contrast agent was topically administered to patients with Barrett's esophagus (BE) undergoing either endoscopic therapy or surveillance” PMID 35299273 ↗ Mar 2022 |
| Target | EGFR | “QRH binds specifically to Epidermal Growth Factor Receptor (EGFR)” NCT03852576 ↗ |
| Target | ERBB2 | “Peptide monomers specific for EGFR and ErbB2 were arranged in a heterodimer configuration” PMID 35299273 ↗ Mar 2022 |